Deciphering the molecular heterogeneity of HER2-positive breast cancer: the critical interplay of hormone receptor status and transcriptomic landscapes Authors: Ilker Sengul, Demet Sengul, Cagri Akalin Published: 2026 ABSTRACT AbstractThe clinical management of HER2-positive breast cancer is undergoing a paradigm shift, recognizing that hormone receptor (HR) co-expression defines a fundamental biological dichotomy rather than a minor clinical variation. This perspective evaluates the profound heterogeneity within the HER2-positive subclass, where HR status acts as a master regulator of genomic landscapes and patient outcomes. Evidence from large-scale database analyses reveals that HR+/HER2 + malignancies are associated with a significant survival advantage, contrasting with the heightened phenotypic aggression and advanced staging characteristic of HR-negative disease. At the molecular level, this divergence is underpinned by distinct transcriptomic profiles; specifically, the enrichment of drug-metabolizing pathways—including cytochrome P450 and retinol metabolism involving CYP2A6 and UGT2B7—suggests a mechanism for superior endocrine sensitivity and modulated apoptotic signaling in the double-positive cohort. Furthermore, the tumor microenvironment reflects this biological disparity, with HR status potentially governing local immune responses, as evidenced by the differential infiltration of resting mast cells versus plasma cells. Of note, while somatic mutations in TP53 and PIK3CA persist across both cohorts, the unique metabolic and immunological milieus confirm that these subtypes represent biologically discrete entities. Moving forward, the “HER2-positive” designation must be refined through integrated, biomarker-driven frameworks. Incorporating these molecular nuances into prospective clinical trials is essential for optimizing therapeutic de-escalation and overcoming the persistent challenges of resistance in HER2-targeted care.Keywords: HR status, HER2 positive, Breast cancer, Prognostic factors, Pathology Dear Editor, The recent investigation by Shi et al., exploring the clinicopathological characteristics and prognostic determinants of HER2-positive (HER2+) breast cancer based on hormone receptor (HR) status, represents a significant contribution to our understanding of this heterogeneous disease (Shi et al. 2025). By leveraging the expansive SEER Plus and TCGA databases, the authors have provided a robust framework for conceptualizing why patients within the same HER2 + subclass exhibit markedly divergent clinical trajectories. As such, the study’s findings—that HR+/HER2 + patients enjoy a profound survival advantage (OS and BCSS) compared to their HR− counterparts—underscore a fundamental biological dichotomy. Particularly compelling is the revelation that HR−/HER2 + malignancies are characterized by aggressive features, including larger tumor size and advanced AJCC staging. This phenotypic aggression appears to be underpinned by a distinct transcriptomic milieu. Specifically, the HR+ group exhibited higher enrichment in critical metabolic pathways, such as drug metabolism-cytochrome P450 and retinol metabolism. These pathways, involving genes like CYP2A6 and UGT2B7, are pivotal in modulating the efficacy of endocrine therapies and retinoic acid-induced apoptosis. Furthermore, the nuances of the tumor microenvironment merit closer clinical attention. The enrichment of resting mast cells in the HR+/HER2 + group, in contrast to the abundance of plasma cells in the HR−/HER2 + group, suggests that HR status may act as a regulator of the local immune response. However, it is imperative to acknowledge that HR “positivity” in clinical practice often represents a biological continuum rather than a simple binary classifier. The datasets utilized by Shi et al. rely on a categorical distinction that may simplify a more complex spectrum. Tumors with low ER expression (1–10% by immunohistochemistry) frequently exhibit molecular characteristics and clinical behaviors—including chemotherapy sensitivity and endocrine resistance—that parallel those of ER-negative disease. Consequently, the superior long-term outcomes in the double-positive cohort are likely driven by tumors with high ER expression, whereas the “ER-low” subgroup may represent a unique “intermediate” entity within the HER2 + landscape. While somatic mutation rates in genes like TP53 (52% in HR + vs. 50% in HR−) and PIK3CA (28% in HR + vs. 32% in HR−) show considerable overlap within the limited TCGA cohort, the cumulative evidence from transcriptomic and clinical data reinforces the view that these are biologically distinct entities. As we move toward an era of de-escalation and increasingly personalized care, the work of Shi et al. reminds us that the “HER2-positive” label is a starting point, not a final diagnosis. Future prospective trials must focus on integrating these transcriptomic profiles and the nuances of HR expression levels to refine therapeutic strategies and overcome the persistent challenge of HER2-targeted therapy resistance. Author contributions IS: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing-original draft, Writing-review&editing. DS: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing-original draft, Writing-review&editing. CA: Investigation, Methodology, Project administration, Validation, Visualization. Funding None declared. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Artificial intelligence No generative artificial intelligence (AI) or AI-assisted technologies have been used in the creation and production of this article. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.